Surgical Navigation Systems in New York

Caira Surgical is a New York-based medical technology company founded in 2019, specializing in advanced software, scanning, and precision radar technologies for orthopedic joint replacement surgery. The company develops radar-based surgical tracking systems delivering sub-millimeter accuracy and navigation platforms designed to enhance surgical precision, reduce setup time, and improve patient outcomes. Caira's proprietary technology is protected by multiple U.S. patents (11,432,882, 11,351,007, 11,510,739, with additional patents pending). The company's first product is a navigation system for knee replacement utilizing fast anatomic landmark registration, with planned expansion to hip, shoulder, and spine procedures. Caira emphasizes reliability, intuitive adoption, efficiency (5x reduction in technology setup time), and affordability (10x cost improvement over conventional systems), making advanced navigated and robotic surgery accessible to diverse surgical settings.

Soteria Medical B.V. is a specialized medical device manufacturer focused on MRI-guided in-bore prostate biopsy solutions. The company has developed a proprietary Remote Controlled Manipulator (RCM)—a fully MRI-compatible robotic device for precision prostate interventions. The RCM enables real-time, near real-time targeting of suspicious prostate lesions within the MRI bore, significantly improving diagnostic accuracy for prostate cancer detection and reducing the need for multiple unnecessary biopsy cores. The RCM system addresses key clinical challenges: it delivers high diagnostic accuracy (reported 70% prostate cancer detection rates), reduces procedure duration (typically under 30 minutes), minimizes patient discomfort by eliminating general anesthesia, and improves specimen quality for pathological analysis. The device features intuitive planning software and remote needle-guide positioning, enabling radiologists to perform precise, guided biopsies with minimal patient motion and reduced in-bore time. Soteria Medical's technology has been validated by leading radiologists across multiple institutions in Europe (Spain, Italy, Netherlands, France, Norway), with testimonials emphasizing clinical safety, diagnostic efficiency, and positive patient experience compared to transrectal ultrasound (TRUS) guidance. The company's offering is positioned for hospital radiology departments and diagnostic imaging centers specializing in urologic oncology and prostate cancer diagnosis. Recent market recognition includes CMS introduction of dedicated CPT codes (55713, 55714) for in-bore MR-guided prostate biopsy, reflecting clinical differentiation and reimbursement support in the US market. Soteria Medical is an active participant in major medical imaging conferences (ECR).

DIXI Medical is a specialized neurosurgical device manufacturer with over 50 years of expertise in stereotactic electroencephalography (SEEG) systems and functional neurosurgery. The company develops high-precision intracerebral electrodes, intraoperative neurophysiological monitoring systems, and stereotactic implantation accessories for epilepsy diagnosis, treatment, and brain research applications. Core product lines include MICRODEEP® SEEG electrodes (sterile, single-use with up to 18 contacts and 0.8 mm diameter for deep brain exploration and thermocoagulation), MICRODEEP® Micro-Macro electrodes (for simultaneous multi-scale neuronal recording bridging clinical and research use), and Cortical IOM electrodes for intraoperative real-time cortical monitoring and stimulation. The company also manufactures dedicated stereotactic implantation instruments and accessories. DIXI Medical serves epilepsy centers and functional neurosurgery programs in over 40 countries and supports SEEG training and research initiatives globally. Manufacturing capabilities include microtechnical precision engineering, sterilization, and quality assurance aligned with medical device standards. The company emphasizes clinical collaboration with neurosurgeons, neurologists, and researchers, with field-based clinical support teams and ongoing investment in training programs for healthcare professionals. Products are designed for compatibility with robotic stereotactic systems and are used in both surgical and research settings.

Anschel Technology Inc. manufactures the SightSaver™, an FDA-approved and patented device for eliciting visual evoked potentials (VEPs) during intraoperative monitoring. The device is designed to prevent post-operative visual loss (POVL)—a serious complication affecting several thousand patients annually in the United States following non-ocular surgical procedures such as spine surgery. The SightSaver™ addresses critical gaps in existing visual stimulation approaches by providing a hygienic, safe, comfortable, and reliable alternative to low-quality, non-hygienic, and unreliable legacy stimulators. The company was founded in 2011 by Dr. David Anschel, a board-certified neurologist and clinical neurophysiologist with extensive academic credentials and research background. The SightSaver products enable perioperative vision risk management through real-time intraoperative visual monitoring, supporting surgical teams in detecting and mitigating vision loss during high-risk procedures.